221 related articles for article (PubMed ID: 18483287)
1. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
4. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
[TBL] [Abstract][Full Text] [Related]
7. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
8. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
9. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
10. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Wechter WJ; Leipold DD; Murray ED; Quiggle D; McCracken JD; Barrios RS; Greenberg NM
Cancer Res; 2000 Apr; 60(8):2203-8. PubMed ID: 10786685
[TBL] [Abstract][Full Text] [Related]
11. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.
Lai MD; Chen CS; Yang CR; Yuan SY; Tsai JJ; Tu CF; Wang CC; Yen MC; Lin CC
Cancer Gene Ther; 2010 Mar; 17(3):203-11. PubMed ID: 19851354
[TBL] [Abstract][Full Text] [Related]
12. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Ravillah D; Mohammed A; Qian L; Brewer M; Zhang Y; Biddick L; Steele VE; Rao CV
J Pharmacol Exp Ther; 2014 Jan; 348(1):59-68. PubMed ID: 24218540
[TBL] [Abstract][Full Text] [Related]
14. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
15. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice.
Raina K; Singh RP; Agarwal R; Agarwal C
Cancer Res; 2007 Jun; 67(12):5976-82. PubMed ID: 17575168
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
[TBL] [Abstract][Full Text] [Related]
17. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):980-8. PubMed ID: 16467113
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
[TBL] [Abstract][Full Text] [Related]
19. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
20. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.
El Touny LH; Banerjee PP
Carcinogenesis; 2007 Aug; 28(8):1710-7. PubMed ID: 17468512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
